[go: up one dir, main page]

MA47408B1 - Traitement du cancer - Google Patents

Traitement du cancer

Info

Publication number
MA47408B1
MA47408B1 MA47408A MA47408A MA47408B1 MA 47408 B1 MA47408 B1 MA 47408B1 MA 47408 A MA47408 A MA 47408A MA 47408 A MA47408 A MA 47408A MA 47408 B1 MA47408 B1 MA 47408B1
Authority
MA
Morocco
Prior art keywords
cancer treatment
erdafitinib
relates
present
treating cancer
Prior art date
Application number
MA47408A
Other languages
English (en)
French (fr)
Other versions
MA47408A (fr
Inventor
Kim Stuyckens
Ruixo Juan Perez
Porre Peter De
Anjali Avadhani
Yohann Loriot
Arlene Siefker-Radtke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47408A publication Critical patent/MA47408A/fr
Publication of MA47408B1 publication Critical patent/MA47408B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/575—
    • G01N33/57585—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA47408A 2017-12-20 2018-02-02 Traitement du cancer MA47408B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17209098 2017-12-20
PCT/EP2018/052694 WO2018141921A1 (en) 2017-02-06 2018-02-02 Cancer treatment

Publications (2)

Publication Number Publication Date
MA47408A MA47408A (fr) 2019-12-11
MA47408B1 true MA47408B1 (fr) 2023-08-31

Family

ID=60702421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47408A MA47408B1 (fr) 2017-12-20 2018-02-02 Traitement du cancer

Country Status (5)

Country Link
EA (1) EA201991818A1 (zh)
MA (1) MA47408B1 (zh)
PT (1) PT3576740T (zh)
TW (1) TWI798199B (zh)
WO (1) WO2018141921A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7761485B2 (ja) * 2018-09-21 2025-10-28 ヤンセン ファーマシューティカ エヌ．ベー． 胆管癌の処置
EP3898615A1 (en) * 2018-12-19 2021-10-27 Array Biopharma, Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
US12180207B2 (en) 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
WO2020190606A1 (en) * 2019-03-15 2020-09-24 Poly-Med, Inc. In situ gel-forming delivery systems, methods and compositions
WO2020201138A1 (en) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130460A1 (en) * 2019-03-29 2020-10-08 Anne Elizabeth O'HAGAN Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
MX2021014524A (es) * 2019-05-31 2022-05-19 Qed Therapeutics Inc Metodos para tratar canceres del sistema urinario.
US12414947B2 (en) 2019-12-09 2025-09-16 Cedars-Sinai Medical Center Use of FGFR inhibitors for treatment of idiopathic short stature
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
BR112022015827A2 (pt) * 2020-02-12 2022-10-04 Janssen Pharmaceutica Nv Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco
WO2022061075A1 (en) * 2020-09-17 2022-03-24 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Also Published As

Publication number Publication date
TW201839399A (zh) 2018-11-01
TWI798199B (zh) 2023-04-11
EA201991818A1 (ru) 2020-02-05
WO2018141921A1 (en) 2018-08-09
MA47408A (fr) 2019-12-11
PT3576740T (pt) 2023-08-18

Similar Documents

Publication Publication Date Title
MA47408B1 (fr) Traitement du cancer
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
IL283838A (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3478286A4 (en) METHOD FOR TREATING OVARY CANCER
EP3813806A4 (en) Methods of treating mitochondrial dysfunction
MA49760B1 (fr) Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EP2992908A4 (en) METHOD FOR THE SURFACE TREATMENT OF AN IMPLANT
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
MA46459A (fr) Méthode de traitement de lésions rénales aiguës
EP3580185A4 (en) Process for the treatment of sludge
EP3820461A4 (en) METHODS OF TREATMENT OF CANCER
EP3937964A4 (en) TREATMENT OF ONCOGENE-DRIVEN CANCERS
EP3775171A4 (en) METHODS OF TREATMENT OF MINIMAL RESIDUAL CANCER
EP3684342A4 (en) TREATMENT PROCEDURES
EA201792610A1 (ru) Способ лечения неврологического заболевания
EP3952858A4 (en) METHODS OF TREATMENT OF TUMOR
EP3769897A4 (en) LASER PROCESSING MACHINE AND LASER PROCESSING METHOD
EP3787625A4 (en) METHODS OF TREATMENT OF CANCER
EP3407858A4 (en) METHOD FOR TREATING THE APPEARANCE OF THINNING HAIR
EP3672689A4 (en) METHOD OF TREATMENT OF A NEUROENDOCRINE TUMOR
EP3638630A4 (en) METHOD OF TREATMENT OF SLUDGE
EP3713576A4 (en) METHOD OF CANCER THERAPY
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MA37475A1 (fr) Biomarqueurs pour thérapie par inhibiteur de iap